The FDA approves Kite's CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence
J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing
Susan G. Komen and the Breast Cancer Research Foundation are focusing on raising awareness and research money for the deadliest forms of the disease.
Patients complain about positive healthcare ads; some drugmakers skirt Open Payment rules; new law requires disclosure of drug price hikes in California
DKMS worked with Marino on PR for the campaign and with Area 23 on its Comic Con booth.
The FDA wants to improve the generic drug approval process; Allergan CEO responds to criticism of patent deal; breast cancer death rate dropped 40%
Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts
The new brand campaign, Attacking Cancer from Every Angle, showcases all the services the organization provides.
The FDA approves first cancer biosimilar; it also approves Bayer's new lymphoma drug; clinical-trial participation for gynecological cancer drops
Teva names new CEO; Allergan transfers Restasis patent to skirt competition; Google invests in oncology
600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar
The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.
The FDA approves Ironwood's gout drug; GSW names new president; Samsung and Takeda to partner on biologic development
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
Celgene and Agios secure FDA approval for AML drug Idhifa; GSK hires chief digital and technology officer; Pfizer wants tax reform before M&A engagement
Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug
The FDA approves J&J psoriasis drug; PARP inhibitors are not cost-effective, ICER says; Verily releases mosquitoes to combat Zika
The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial
Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.
Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.
The executive director of oncology marketing is fascinated by the resilience of the human body.
Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation
Industry leaders discussed why a social-centric approach is especially important in oncology, particularly as it relates to health systems, interactions with healthcare providers, and family support.
This includes concerns about the effectiveness — and cost-effectiveness — of drugs like Merck's Keytruda and Bristol-Myers Squibb's Opdivo, in combination or alone.
BMS partners on Opdivo combo; one-quarter of insurers have signed an outcomes-based contract with a drugmaker; rebates do not lead to savings for Medicare beneficiaries
Keytruda receives first approval based on a genetic feature and not tumor's location; Alexion reps reportedly crossed ethical lines; profits up at insurers
An FDA advisory committee is expected to decide Wednesday whether to recommend neratinib for approval.
Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness